Prolactin-releasing peptide (PrRP) has been proposed to mediate the central satiating effects of cholecystokinin (CCK) through the vagal CCK1 receptor. PrRP acts as an endogenous ligand of G protein-coupled receptor 10 (GPR10), which is expressed at the highest levels in brain areas related to food intake regulation, e.g., the paraventricular hypothalamic nucleus (PVN) and nucleus of the solitary tract (NTS). The NTS and PVN are also significantly activated after peripheral CCK administration. The aim of this study was to determine whether the endogenous PrRP neuronal system in the brain is involved in the central anorexigenic effect of the peripherally administered CCK agonist JMV236 or the CCK1 antagonist devazepide and whether the CCK system is involved in the central anorexigenic effect of the peripherally applied lipidized PrRP analog palm-PrRP31 in fasted lean mice. The effect of devazepide and JMV236 on the anorexigenic effects of palm-PrRP31 as well as devazepide combined with JMV236 and palm-PrRP31 on food intake and Fos cell activation in the PVN and caudal NTS was examined. Our results suggest that the anorexigenic effect of JMV236 is accompanied by activation of PrRP neurons of the NTS in a CCK1 receptor-dependent manner. Moreover, while the anorexigenic effect of palm-PrRP31 was not affected by JMV236, it was partially attenuated by devazepide in fasted mice. The present findings indicate that the exogenously influenced CCK system may be involved in the central anorexigenic effect of peripherally applied palm-PrRP31, which possibly indicates some interaction between the CCK and PrRP neuronal systems.

• MeSH
• anorektika aplikace a dávkování   MeSH
• antagonisté hormonů aplikace a dávkování   MeSH
• chemokiny CC účinky léků   metabolismus   MeSH
• cholecystokinin metabolismus   MeSH
• devazepid aplikace a dávkování   MeSH
• hormon uvolňující prolaktin aplikace a dávkování   analogy a deriváty   MeSH
• injekce intraperitoneální MeSH
• injekce subkutánní MeSH
• myši inbrední C57BL MeSH
• myši MeSH
• nucleus paraventricularis hypothalami účinky léků   metabolismus   MeSH
• nucleus solitarius účinky léků   metabolismus   MeSH
• omezení příjmu potravy MeSH
• peptidové fragmenty aplikace a dávkování   MeSH
• přijímání potravy účinky léků   MeSH
• protoonkogenní proteiny c-fos metabolismus   MeSH
• signální transdukce MeSH
• sinkalid aplikace a dávkování   analogy a deriváty   MeSH
• stravovací zvyklosti účinky léků   MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• anorektika MeSH
• antagonisté hormonů MeSH
• Ccl28 protein, mouse MeSH Prohlížeč
• chemokiny CC MeSH
• cholecystokinin MeSH
• devazepid MeSH
• Fos protein, mouse MeSH Prohlížeč
• hormon uvolňující prolaktin MeSH
• JMV 236 MeSH Prohlížeč
• palm11-PrRP31 MeSH Prohlížeč
• peptidové fragmenty MeSH
• protoonkogenní proteiny c-fos MeSH
• sinkalid MeSH

Novel aminonaphthylcysteine (ANC) adducts, formed via naphthylnitrenium ions and/or their metabolic precursors in the biotransformation of naphthylamines (NA) and nitronaphthalenes (NN), were identified and quantified in globin of rats dosed intraperitoneally with 0.16 mmol/kg b.w. of 1-NA, 1-NN, 2-NA and 2-NN. Using HPLC-ESI-MS2 analysis of the globin hydrolysates, S-(1-amino-2-naphthyl)cysteine (1A2NC) together with S-(4-amino-1-naphthyl)cysteine (4A1NC) were found in rats given 1-NA or 1-NN, and S-(2-amino-1-naphthyl)cysteine (2A1NC) in those given 2-NA or 2-NN. The highest level of ANC was produced by the most mutagenic and carcinogenic isomer 2-NA (35.8 ± 5.4 nmol/g globin). The ratio of ANC adduct levels for 1-NA, 1-NN, 2-NA and 2-NN was 1:2:100:3, respectively. Notably, the ratio of 1A2NC:4A1NC in globin of rats dosed with 1-NA and 1-NN differed significantly (2:98 versus 16:84 respectively), indicating differences in mechanism of the adduct formation. Moreover, aminonaphthylmercapturic acids, formed via conjugation of naphthylnitrenium ions and/or their metabolic precursors with glutathione, were identified in the rat urine. Their amounts excreted after dosing rats with 1-NA, 1-NN, 2-NA and 2-NN were in the ratio 1:100:40:2, respectively. For all four compounds tested, haemoglobin binding index for ANC was several-fold higher than that for the sulphinamide adducts, generated via nitrosoarene metabolites. Due to involvement of electrophilic intermediates in their formation, ANC adducts in globin may become toxicologically more relevant biomarkers of cumulative exposure to carcinogenic or non-carcinogenic arylamines and nitroarenes than the currently used sulphinamide adducts.

• Klíčová slova
• Arylamines, Arylnitrenium ions, Biomarker, Carcinogens, Globin adducts, Nitroarenes,
• MeSH
• 1-naftylamin aplikace a dávkování   metabolismus   toxicita   MeSH
• 2-naftylamin aplikace a dávkování   metabolismus   toxicita   MeSH
• acetylcystein analogy a deriváty   moč   MeSH
• biologické markery krev   moč   MeSH
• cystein MeSH
• globiny metabolismus   MeSH
• injekce intraperitoneální MeSH
• krysa rodu Rattus MeSH
• naftaleny aplikace a dávkování   krev   toxicita   MeSH
• potkani Wistar MeSH
• vazba proteinů MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• srovnávací studie MeSH
• Názvy látek
• 1-naftylamin MeSH
• 1-nitronaphthalene MeSH Prohlížeč
• 2-naftylamin MeSH
• 2-nitronaphthalene MeSH Prohlížeč
• acetylcystein MeSH
• biologické markery MeSH
• cystein MeSH
• globiny MeSH
• naftaleny MeSH

The plant extract aristolochic acid (AA), containing aristolochic acid I (AAI) and II (AAII) as major components, causes aristolochic acid nephropathy and Balkan endemic nephropathy, unique renal diseases associated with upper urothelial cancer. Differences in the metabolic activation and detoxification of AAI and AAII and their effects on the metabolism of AAI/AAII mixture in the plant extract might be of great importance for an individual's susceptibility in the development of AA-mediated nephropathies and malignancies. Here, we investigated in vivo metabolism of AAI and AAII after ip administration to Wistar rats as individual compounds and as AAI/AAII mixture using high performance liquid chromatography/electrospray ionization mass spectrometry. Experimental findings were supported by theoretical calculations using density functional theory. We found that exposure to AAI/AAII mixture affected the generation of their oxidative and reductive metabolites formed during Phase I biotransformation and excreted in rat urine. Several Phase II metabolites of AAI and AAII found in the urine of exposed rats were also analyzed. Our results indicate that AAI is more efficiently metabolized in rats in vivo than AAII. Whereas AAI is predominantly oxidized during in vivo metabolism, its reduction is the minor metabolic pathway. In contrast, AAII is mainly metabolized by reduction. The oxidative reaction only occurs if aristolactam II, the major reductive metabolite of AAII, is enzymatically hydroxylated, forming aristolactam Ia. In AAI/AAII mixture, the metabolism of AAI and AAII is influenced by the presence of both AAs. For instance, the reductive metabolism of AAI is increased in the presence of AAII while the presence of AAI decreased the reductive metabolism of AAII. These results suggest that increased bioactivation of AAI in the presence of AAII also leads to increased AAI genotoxicity, which may critically impact AAI-mediated carcinogenesis. Future studies are needed to explain the underlying mechanism(s) for this phenomenon.

• MeSH
• hmotnostní spektrometrie s elektrosprejovou ionizací MeSH
• injekce intraperitoneální MeSH
• krysa rodu Rattus MeSH
• kyseliny aristolochové aplikace a dávkování   metabolismus   moč   MeSH
• potkani Wistar MeSH
• teorie funkcionálu hustoty MeSH
• vysokoúčinná kapalinová chromatografie MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• aristolochic acid I MeSH Prohlížeč
• aristolochic acid II MeSH Prohlížeč
• kyseliny aristolochové MeSH

Beta-hydroxy-beta-methyl butyrate (HMB) is a unique product of leucine catabolism with positive effects on protein balance. We have examined the effects of HMB (200 mg/kg/day via osmotic pump for 7 days) on rats with diabetes induced by streptozotocin (STZ, 100 mg/kg intraperitoneally). STZ induced severe diabetes associated with muscle wasting, decreased ATP in the liver, and increased α-ketoglutarate in muscles. In plasma, liver, and muscles increased branched-chain amino acids (BCAAs; valine, isoleucine, and leucine) and decreased serine. The decreases in mass and protein content of muscles and increases in BCAA concentration were more pronounced in extensor digitorum longus (fast-twitch muscle) than in soleus muscle (slow-twitch muscle). HMB infusion to STZ-treated animals increased glycemia and serine in the liver, decreased BCAAs in plasma and muscles, and decreased ATP in the liver and muscles. The effects of HMB on the weight and protein content of tissues were nonsignificant. We concluded that fast-twitch muscles are more sensitive to STZ than slow-twitch muscles and that HMB administration to STZ-treated rats has dual effects. Adjustments of BCAA concentrations in plasma and muscles and serine in the liver can be considered beneficial, whereas the increased glycemia and decreased ATP concentrations in the liver and muscles are detrimental.

• Klíčová slova
• ATP depletion, branched-chain amino acids, ketoglutarate, muscles, serine,
• MeSH
• aminokyseliny aplikace a dávkování   farmakologie   MeSH
• diabetes mellitus 1. typu chemicky indukované   farmakoterapie   metabolismus   MeSH
• injekce intraperitoneální MeSH
• injekce subkutánní MeSH
• játra účinky léků   metabolismus   MeSH
• kosterní svaly účinky léků   metabolismus   MeSH
• krysa rodu Rattus MeSH
• potkani Wistar MeSH
• streptozocin aplikace a dávkování   MeSH
• valeráty aplikace a dávkování   farmakologie   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• aminokyseliny MeSH
• beta-hydroxyisovaleric acid MeSH Prohlížeč
• streptozocin MeSH
• valeráty MeSH

BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for peritoneal surface malignancies with efficacy reported in many trials. Discrepancies, however, in the indication criteria, the extent of the surgical procedure, HIPEC regimens and toxicity evaluation represent a problem when comparing this method with other therapeutic modalities. METHODS: We describe the initial experience with CRS/HIPEC using different chemotherapy regimens (oxaliplatin, cisplatin, mitomycin C and doxorubicin) at the Comprehensive Oncology Centre Olomouc. RESULTS: A perioperative mortality of 2% and perioperative morbidity of 11%, according to Clavien-Dindo were observed. Interestingly, all these patients underwent HIPEC with oxaliplatin 460 mg/m2. The median duration of admission to hospital was 6 days in the intensive care unit (range 2-28 days) and 7 days in the surgical ward (range 1-21 days). Hospital admission did not exceed 2 weeks in 75% of patients. These results are consistent with the published results of large centres performing this treatment modality mainly due to pre-operative preparation of patients and pre-treatment and post-treatment management of HIPEC/CRS toxicity. Evaluation of the efficacy in terms of time to progression and overall survival (OS) is limited by the short follow up period. CONCLUSION: CRS/HIPEC performed is a safe method with low perioperative mortality.

• Klíčová slova
• adverse events, cisplatin, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, mitomycin C, morbidity, oxaliplatin, toxicity,
• MeSH
• cisplatina terapeutické užití   MeSH
• cytoredukční chirurgie metody   MeSH
• dospělí MeSH
• doxorubicin terapeutické užití   MeSH
• injekce intraperitoneální MeSH
• kombinovaná terapie MeSH
• lidé středního věku MeSH
• lidé MeSH
• mitomycin terapeutické užití   MeSH
• oxaliplatin terapeutické užití   MeSH
• peritoneální nádory farmakoterapie   chirurgie   MeSH
• protokoly protinádorové kombinované chemoterapie terapeutické užití   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Česká republika MeSH
• Názvy látek
• cisplatina MeSH
• doxorubicin MeSH
• mitomycin MeSH
• oxaliplatin MeSH

A series of 2-aryl-2-(pyridin-2-yl)acetamides were synthesized and screened for their anticonvulsant activity in animal models of epilepsy. The compounds were broadly active in the 'classical' maximal electroshock seizure (MES) and subcutaneous Metrazol (scMET) tests as well as in the 6 Hz and kindling models of pharmacoresistant seizures. Furthermore, the compounds showed good therapeutic indices between anticonvulsant activity and motor impairment. Structure-activity relationship (SAR) trends clearly showed the highest activity resides in unsubstituted phenyl derivatives or compounds having ortho- and meta- substituents on the phenyl ring. The 2-aryl-2-(pyridin-2-yl)acetamides were derived by redesign of the cardiotoxic sodium channel blocker Disopyramide (DISO). Our results show that the compounds preserve the capability of the parent compound to inhibit voltage gated sodium currents in patch-clamp experiments; however, in contrast to DISO, a representative compound from the series 1 displays high levels of cardiac safety in a panel of in vitro and in vivo experiments.

• Klíčová slova
• Anticonvulsant agent, Cardiac safety, Disopyramide, Drug discovery, Drug repositioning, Medicinal Chemistry, Refractory epilepsy, Sodium channel blocker, Structure-activity relationships, Voltage-gated sodium channel,
• MeSH
• acetamidy aplikace a dávkování   chemie   terapeutické užití   MeSH
• antikonvulziva aplikace a dávkování   chemie   terapeutické užití   MeSH
• disopyramid aplikace a dávkování   chemie   terapeutické užití   MeSH
• elektrický šok MeSH
• injekce intraperitoneální MeSH
• injekce subkutánní MeSH
• krysa rodu Rattus MeSH
• molekulární struktura MeSH
• myši MeSH
• pentylentetrazol aplikace a dávkování   MeSH
• potkani Wistar MeSH
• vztah mezi dávkou a účinkem léčiva MeSH
• vztahy mezi strukturou a aktivitou MeSH
• záchvaty chemicky indukované   farmakoterapie   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• myši MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• acetamidy MeSH
• antikonvulziva MeSH
• disopyramid MeSH
• pentylentetrazol MeSH

The effectiveness of cell transplantation can be improved by optimization of the transplantation site. For some types of cells that form highly oxygen-demanding tissue, e.g., pancreatic islets, a successful engraftment depends on immediate and sufficient blood supply. This critical point can be avoided when cells are transplanted into a bioengineered pre-vascularized cavity which can be formed using a polymer scaffold. In our study, we tested surface-modified poly(lactide-co-caprolactone) (PLCL) capsular scaffolds containing the pro-angiogenic factor VEGF. After each modification step (i.e., amination and heparinization), the surface properties and morphology of scaffolds were characterized by ATR-FTIR and XPS spectroscopy, and by SEM and AFM. All modifications preserved the gross capsule morphology and maintained the open pore structure. Optimized aminolysis conditions decreased the Mw of PLCL only up to 10% while generating a sufficient number of NH2 groups required for the covalent immobilization of heparin. The heparin layer served as a VEGF reservoir with an in vitro VEGF release for at least four weeks. In vivo studies revealed that to obtain highly vascularized PLCL capsules (a) the optimal VEGF dose for the capsule was 50 μg and (b) the implantation time was four weeks when implanted into the greater omentum of Lewis rats; dense fibrous tissue accompanied by vessels completely infiltrated the scaffold and created sparse granulation tissue within the internal cavity of the capsule. The prepared pre-vascularized pouch enabled the islet graft survival and functioning for at least 50 days after islet transplantation. The proposed construct can be used to create a reliable pre-vascularized pouch for cell transplantation.

• MeSH
• bioinženýrství * MeSH
• experimentální diabetes mellitus chemicky indukované   metabolismus   patologie   MeSH
• fyziologická neovaskularizace * MeSH
• injekce intraperitoneální MeSH
• krevní glukóza analýza   MeSH
• krysa rodu Rattus MeSH
• molekulární struktura MeSH
• polyestery chemie   metabolismus   MeSH
• potkani inbrední LEW MeSH
• streptozocin aplikace a dávkování   MeSH
• tobolky chemie   metabolismus   MeSH
• transplantace Langerhansových ostrůvků * MeSH
• vaskulární endoteliální růstové faktory chemie   metabolismus   MeSH
• velikost částic MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• krevní glukóza MeSH
• poly(lactide) MeSH Prohlížeč
• polyestery MeSH
• streptozocin MeSH
• tobolky MeSH
• vaskulární endoteliální růstové faktory MeSH

Labelling of DNA in replicating cells using 5-bromo-2´-deoxyuridine (BrdU) is widely used, however the rapid clearance and metabolisation of BrdU in the living organism is a critical issue. Although the pharmacokinetic of BrdU in experimental animals is empirically approximated, the exact time-curve remains unknown. Here we present novel method for estimation of the BrdU content in the blood serum. The application is based on the in vitro cocultivation of tumour cells with the examined serum and the subsequent quantification of the incorporated BrdU in the DNA using flow cytometry analysis. Our results demonstrate that this approach can quantify the BrdU concentration in serum at 1 micromol.dm(-3) and might represent an attractive alternative to conventional chromatographic analysis. The employment of tumour cells as "detectors" of the BrdU content in serum provides an advantage over high pressure liquid chromatography (HPLC), as this approach allows us to approximate not only the concentration of BrdU, but also to determine, whether BrdU is present in the blood serum in effective concentration to reliable label all cells undergoing the S-phase of the cell cycle. The presented application might be a helpful tool for studies on pharmacokinetics of BrdU or other thymidine analogues when testing various administration routes or protocols.

• MeSH
• antimetabolity krev   MeSH
• bromodeoxyuridin krev   MeSH
• buněčná adheze MeSH
• buněčné linie MeSH
• injekce intraperitoneální MeSH
• krysa rodu Rattus MeSH
• lidé MeSH
• proliferace buněk účinky léků   MeSH
• průtoková cytometrie MeSH
• vysokoúčinná kapalinová chromatografie MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• antimetabolity MeSH
• bromodeoxyuridin MeSH

Antagonists of GABA(B) receptors are expected to have proconvulsant action also in developing brain. Two antagonists (CGP55845 and CGP46381) were tested in a model of cortical epileptic afterdischarges (ADs) in 12-, 18- and 25-day-old rat pups with implanted electrodes. CGP55845 was dissolved in dimethylsulfoxide and the results demonstrated marked proconvulsant action of this solvent which masked possible action of the antagonist. Water soluble antagonist CGP46381 led to marked potentiation of ADs in 12-day-old animals, its action decreased with age, it was negligible in 25-day-old rats. Our results demonstrated important inhibitory role of GABA(B) receptors at very early stages of maturation.

• MeSH
• akční potenciály účinky léků   MeSH
• antagonisté receptorů GABA-B farmakologie   MeSH
• elektroencefalografie MeSH
• epilepsie myoklonické chemicky indukované   patofyziologie   MeSH
• injekce intraperitoneální MeSH
• konvulziva MeSH
• krysa rodu Rattus MeSH
• kyseliny fosfinové farmakologie   MeSH
• modely nemocí na zvířatech * MeSH
• mozková kůra účinky léků   patofyziologie   MeSH
• potkani Wistar MeSH
• propanolaminy farmakologie   MeSH
• receptory GABA fyziologie   MeSH
• stárnutí MeSH
• synergismus léků MeSH
• věkové faktory MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• 3-aminopropyl-cyclohexylmethylphosphinic acid MeSH Prohlížeč
• antagonisté receptorů GABA-B MeSH
• CGP 55845A MeSH Prohlížeč
• konvulziva MeSH
• kyseliny fosfinové MeSH
• propanolaminy MeSH
• receptory GABA MeSH

Matriptase-2, a membrane protein encoded by the Tmprss6 gene, is a negative regulator of hepcidin expression. Although matriptase-2 has been proposed to cleave membrane hemojuvelin, we have recently found decreased hemojuvelin protein levels in Tmprss6 -/- mice. The purpose of this study was to confirm this observation by determining hemojuvelin protein levels in another strain of mice with disrupted Tmprss6 gene, and to determine the effect of matriptase-2 deficiency on the expression of other membrane proteins participating in the bone morphogenetic protein signal transduction. Mask mice, which lack the proteolytic domain of matriptase-2, displayed decreased liver hemojuvelin protein content, while Id1 mRNA level, an indicator of hemojuvelin-dependent signal transduction, was increased. Protein levels of bone morphogenetic protein receptors Alk3 and Acvr2a were unchanged, and transferrin receptor 2 and neogenin protein levels were slightly decreased. The results confirm that the loss of matriptase-2 increases bone morphogenetic protein-dependent signaling, while paradoxically decreasing liver hemojuvelin protein content. The regulation of transferrin receptor 2 protein levels by transferrin saturation was not affected in mask mice. How the loss of matriptase-2 proteolytic activity leads to decreased hemojuvelin protein levels is at present unclear.

• MeSH
• aktivinové receptory typu II metabolismus   MeSH
• deficit železa MeSH
• down regulace MeSH
• GPI-vázané proteiny MeSH
• inhibitor diferenciace 1 genetika   metabolismus   MeSH
• injekce intraperitoneální MeSH
• játra účinky léků   metabolismus   MeSH
• membránové proteiny nedostatek   genetika   metabolismus   MeSH
• messenger RNA metabolismus   MeSH
• myši inbrední C57BL MeSH
• myši knockoutované MeSH
• myši MeSH
• protein hemochromatózy MeSH
• receptory morfogenetických kostních proteinů typu I metabolismus   MeSH
• receptory transferinu metabolismus   MeSH
• serinové endopeptidasy nedostatek   genetika   MeSH
• železo-dextranový komplex aplikace a dávkování   MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• myši MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• activin receptor type II-A MeSH Prohlížeč
• aktivinové receptory typu II MeSH
• Bmpr1a protein, mouse MeSH Prohlížeč
• GPI-vázané proteiny MeSH
• HJV protein, mouse MeSH Prohlížeč
• Idb1 protein, mouse MeSH Prohlížeč
• inhibitor diferenciace 1 MeSH
• matriptase 2 MeSH Prohlížeč
• membránové proteiny MeSH
• messenger RNA MeSH
• neogenin MeSH Prohlížeč
• protein hemochromatózy MeSH
• receptory morfogenetických kostních proteinů typu I MeSH
• receptory transferinu MeSH
• serinové endopeptidasy MeSH
• TFR2 protein, mouse MeSH Prohlížeč
• železo-dextranový komplex MeSH